About
A propos de nous
Our methods
Updated report
Multilinguality
Help
How to use
Key concepts
FAQ
Contact
Inscription
Connexion
العربية
Deutsch
English
Español
Français
Italiano
Nederlands
Português
中文
×
Adresse électronique:
Mot de passe:
Mot de passe oublié?
×
Edit Thread Title
Thread name
Thread full name
Thread alternative names
Thread phase
×
Delete Thread
Are you sure you want to delete the thread
? This operation cannot be undone.
AUREC-FVIII
ID:
57c2e8ea18d84e5b010d8415
1 Documents
Export all
Document ID
Add to Thread
Thread ID
Merge thread
Close
1 References
( articles)
Revert
Studify
Primary study
Unclassified
6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII
Auteurs
»
Eischer L
,
Gartner V
,
Schulman S
,
Kyrle PA
,
Eichinger S
,
AUREC-FVIII investigators
Journal
»
Annals of hematology
Year
»
2009
Liens
»
Pubmed
DOI
Loading references information
No abstract
Show abstract
Patients with first venous thromboembolism (VTE) and high factor VIII (FVIII) are at increased risk of recurrence. It is unknown whether these patients benefit from prolonged secondary thrombophrophylaxis. In a prospective trial patients with first spontaneous VTE and FVIII levels >230 IU/dl were randomized to discontinue vitamin K Antagonist (VKA) after 6 months or to continue VKA for additional 24 months. Patients were excluded if they had a natural inhibitor deficiency, lupus anticoagulant, cancer, were pregnant, required long-term antithrombotic therapy or had acute-phase reaction. Primary study endpoints were symptomatic recurrent VTE or major bleeding within 2 years. Follow-up was continued beyond 2 years. Of 3,219 screened patients 34 met the inclusion criteria. Mean observation time was 37 months. Two of 17 patients allocated to discontinue VKA and two of 17 patients randomized to prolonged anticoagulation had recurrent VTE within 2 years. In the prolonged treatment group, one patient had recurrence during VKA therapy and one patient 4 weeks after voluntary discontinuation of VKA. One major nonfatal bleeding (severe epistaxis) after 10 months of VKA occurred in the prolonged treatment group. Five patients allocated to prolonged anticoagulation had recurrent VTE after discontinuation of VKA. The probability of recurrence at 2 years after discontinuation of VKA was 30% (95% CI 13-46%). Patients with high FVIII are at increased risk of recurrence. Our findings in a small number of patients indicate that prolonged anticoagulation seems to be effective but that the benefit is not maintained after discontinuation of anticoagulation. © Springer-Verlag 2008.
Hide abstract
Résumé
À propos de cet article
Related evidence
Patients with first venous thromboembolism (VTE) and high factor VIII (FVIII) are at increased risk of recurrence. It is unknown whether these patients benefit from prolonged secondary thrombophrophylaxis. In a prospective trial patients with first spontaneous VTE and FVIII levels >230 IU/dl were randomized to discontinue vitamin K Antagonist (VKA) after 6 months or to continue VKA for additional 24 months. Patients were excluded if they had a natural inhibitor deficiency, lupus anticoagulant, cancer, were pregnant, required long-term antithrombotic therapy or had acute-phase reaction. Primary study endpoints were symptomatic recurrent VTE or major bleeding within 2 years. Follow-up was continued beyond 2 years. Of 3,219 screened patients 34 met the inclusion criteria. Mean observation time was 37 months. Two of 17 patients allocated to discontinue VKA and two of 17 patients randomized to prolonged anticoagulation had recurrent VTE within 2 years. In the prolonged treatment group, one patient had recurrence during VKA therapy and one patient 4 weeks after voluntary discontinuation of VKA. One major nonfatal bleeding (severe epistaxis) after 10 months of VKA occurred in the prolonged treatment group. Five patients allocated to prolonged anticoagulation had recurrent VTE after discontinuation of VKA. The probability of recurrence at 2 years after discontinuation of VKA was 30% (95% CI 13-46%). Patients with high FVIII are at increased risk of recurrence. Our findings in a small number of patients indicate that prolonged anticoagulation seems to be effective but that the benefit is not maintained after discontinuation of anticoagulation. © Springer-Verlag 2008.
Devis de recherche
»
Essai contrôlé randomisé (ECR)